|
|
Podcast: Multidisciplinary Task Force and Position Statement: Mitigating Disease Burden and Health Care Disparities in Relapsed/Refractory Multiple Myeloma
STATEMENT OF NEED
With the complex and rapidly evolving treatment landscape of multiple myeloma, it is vital that clinicians not only understand factors for informing selection of current and emerging combination and sequential therapeutic strategies, but also employ interdisciplinary strategies for reducing disparities in relapsed/refractory multiple myeloma care. The development of novel therapeutic options has significantly improved treatment outcomes for patients with relapsed/refractor... |
|
|
Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disorders: Addressing Unmet Needs with Emerging Therapies
In this Hematology Dialogues, Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disorders: Addressing Unmet Needs with Emerging Therapies, participants will learn about the epidemiology and burden of Epstein-Barr Virus-positive (EBV+) and post-transplant lymphoproliferative disorders (PTLD), differentiate between current and emerging prognostic scoring systems for EBV+ and PTLD to inform treatment decisions, and evaluate the latest clinical evidence of emerging treatment options ... |
|
|
Cracking the Code to Successful Stem Cell Mobilization in Multiple Myeloma
STATEMENT OF NEED
Multiple myeloma is the leading indication of autologous hematopoietic stem cell transplantation (ASCT) in hematologic malignancies, with high-dose therapy followed by ASCT representing a potentially curative treatment modality for eligible patients. Collecting peripheral blood stem cells (PBSCs) is an essential component of ASCT, and the collection of sufficient autologous PBSCs relies on the successful mobilization of hematopoietic stem cells from the bone marrow niche i... |
|